Thursday 7 May, 2026
Introduction: Cyclosporine A (CsA) is increasingly being used in reproductive medicine and pregnancy immunotherapy. However, pregnancy-induced physiological changes may substantially…
Read moreAbstracts
NoLimits.jl: A flexible Julia framework for nonlinear, neural and latent-state mixed-effects modeling
Thursday 7 May, 2026
Introduction/Objectives Hidden Markov models (HMMs) are increasingly applied in pharmacometric disease progression modeling to represent latent disease states and transitions…
Read morePK-DB 2.0: An Open Pharmacokinetics and Pharmacodynamics Database for Pharmacometric Modeling, AI, and Digital Twins
Thursday 7 May, 2026
Introduction: The rapid growth of published pharmacokinetics (PK) and pharmacodynamics (PD) data from clinical and preclinical studies requires structured, interoperable,…
Read moreDevelopment of a mathematical model for the quantitative comparison of RC106 and TMZ efficacy in U87 spheroids
Thursday 7 May, 2026
Introduction: Glioblastoma (GBM) is an aggressive brain tumor with no effective cure. Temozolomide (TMZ) remains the standard chemotherapeutic agent; however,…
Read moreA SYNCHRONOUS JOINT POPULATION PHARMACOKINETIC MODEL ANALYSIS FOR THE SIMULTANEOUS ASSESSMENT OF TWO ACTIVE PHARMACEUTICAL INGREDIENTS
Thursday 7 May, 2026
Objectives In clinical practice, many treatments are given as combination therapies. However, population pharmacokinetic (popPK) analysis typically evaluates each drug…
Read moreExploring the impact of extracorporeal membrane oxygenation (ECMO) therapy on piperacillin pharmacokinetics: do general intensive care unit models perform similarly to ECMO models?
Thursday 7 May, 2026
Introduction ECMO (extracorporeal membrane oxygenation) therapy provides temporary cardiac and/or respiratory support to critically ill patients, and anti-infective agents are…
Read moreEXPLAINABLE DEEP WEIBULL SURVIVAL MODELING FOR PREDICTING TIME TO COGNITIVE IMPAIRMENT IN OLDER ADULTS
Thursday 7 May, 2026
Objectives: The primary objective of this study was to develop an Explainable Deep Survival Analysis framework that predicts the progression…
Read morerock and roll – Deliverables driven by standardized data specifications
Thursday 7 May, 2026
Objectives: The process of creating analysis-ready data deliverables is a vital part of any pharmacometrics workflow, but is prone to…
Read moreSTREAMLINED OPEN-SOURCE PBPK DDI ASSESSMENTS USING THE OSP SUITE WITH R-BASED esqlabsR/ESQapp WORKFLOWS
Thursday 7 May, 2026
Objectives: Drug-drug interactions (DDIs) are a major concern in drug development and clinical practice. Mechanistic physiologically based pharmacokinetic (PBPK) modeling…
Read moreBeyond the Michaelis–Menten: A Modified Enzyme Kinetics Framework for Bottom-Up PBPK Modeling and Its Implementation in the Simcyp® Platform
Thursday 7 May, 2026
Introduction In conventional IVIVE–PBPK (In Vitro-In Vivo Extrapolation and Physiologically Based Pharmacokinetic) modeling, hepatic intrinsic clearance (CLint) is typically derived…
Read more